Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

Speaker 4: (00:32)
 Please give the audience a little information about yourself and your background.

Speaker 4: (02:12)
 Please give the audience a brief overview of this assay.

Speaker 4: (04:34)
 Which patients should have this testing and when should it be performed? 

Speaker 4: (05:50)
 What alternative testing options are available and how do these compare?

Speaker 4: (06:47)
 How are the results used in patient care?